Many people with COPD can control their symptoms by using inhaled medicines each day. But inhaled medicines may not offer enough relief for people who also have high levels of a type of white blood ...

Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher dose Dupixent in these children Data reinforce ...

Most people with asthma are able to control their symptoms by using inhaled medicines each day. But for some people with severe asthma, inhaled medicines are not enough to keep symptoms under control.

About the Dupixent Pediatric Eosinophilic Esophagitis Trial The Phase 3 randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of Dupixent in children aged 1 to 11 years ...

Dupixent® (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old 68% of children on ...

In the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite standard-of-care antihistamine treatment Dupixent, which ...

TARRYTOWN, N.Y. and PARIS, June 26, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the New England Journal of Medicine (NEJM) has published results ...

Majority of patients in this age group with eosinophilic esophagitis (EoE) receiving Dupixent achieved histologic remission, with improvements sustained up to one year Dupixent is the first and only ...